Discovery approaches for novel dyslipidemia drugs

Current Drug Discovery Technologies

Volumn 12, Issue 2, 2015, Pages 90-116

  Maqbool, Faheem ^a   Safavi, Malihe ^c   Bahadar, Haji ^a   Rahimifard, Mahban ^a   Niaz, Kamal ^a   Abdollahi, Mohammad ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRANIAN RESEARCH ORGANIZATION FOR SCIENCE AND TECHNOLOGY IROST   (Iran)

Author keywords

Cardiovascular disease; Diabetes mellitus; Dyslipidemia; FXR modulators; PCSK9 inhibitors; Statins; Synthetic drugs; Virtual screening

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ALEGLITAZAR; ANTILIPEMIC AGENT; ATORVASTATIN; CARRIER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; MURAGLITAZAR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; ROSUVASTATIN; TESAGLITAZAR; THYROMIMETIC AGENT; UNCLASSIFIED DRUG; CHOLESTEROL; PCSK9 PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SERINE PROTEINASE; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; HUMAN; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGONISTS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECTS; DYSLIPIDEMIAS; EXPERIMENTAL THERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; TRENDS;

CARDIOVASCULAR DISEASES; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; MOLECULAR TARGETED THERAPY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; THERAPIES, INVESTIGATIONAL; TRIGLYCERIDES;

EID: 84939783618     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/1570163812666150702121809     Document Type: Article

References (142)

1. Mackenbach J. The epidemiologic transition theory. J Epidemiol Community Health 1994;48:329-31.
2. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrology Dialysis Transplantation 2003;18(9):1731-1740.
3. Lê KA, Ith M, Kreis R, et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 2009;89(6):1760-1765.
4. Varady KA, Jones PJ. Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels? J Nutr 2005;135:1829-35.
5. Kannel WB, Dawber TR, Kagan A, et al. Factors of Risk in the Development of Coronary Heart Disease-Six-Year Follow-up Experience The Framingham Study. Ann Intern Med 1961;55:33-50.
6. Taskinen MR. Diabetic dyslipidemia. Atherosclerosis Supplements 2002;3:47-51.
7. Ling H, Burns TL, Hilleman DE. Novel strategies for managing dyslipidemia: treatment beyond statins. Postgrad Med 2012;124:43-54.
8. Meagher EA. Addressing cardiovascular disease in women: focus on dyslipidemia. J Am Board Fam Med 2004;17:424-37.
9. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Bio 2008;28:1225-36.
10. Haffner SM, Lehto S, Rönnemaa T, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. NEJM 1998;339:229-34.
11. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 2000;102:1014-9.
12. Isomaa B, Henricsson M, Almgren P, et al. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001;44:1148-54.
13. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9, 416 patients. Am J Cardiol 2003;92(6):670-676.
14. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. NEJM 2005;353(3):238-248.
15. Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43(4):589-599.
16. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. The Lancet 2010;376(9756):1916-1922.
17. Blank R, La Salle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-Pill Therapy in the Treatment of Concomitant Hypertension and Dyslipidemia (The Amlodipine/Atorvastatin Gemini Study). J Clin Hypertens 2005;7(5):264-273.
18. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002;51(3):334-342.
19. Stojakovic T, Claudel T, Putz-Bankuti C, et al. Lowdose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010;209(1):178-183.
20. Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009;8:308-20.
21. Chapman MJ, McTaggart F. Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atheroscler Suppl 2002;2:33-7.
22. Jones SP, Gibson MF, Rimmer DM, et al. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am CollCardiol 2002;40:1172-8.
23. Phase III study of rosuvastatin and fenofibrate versus rosuvastatin in mixed dyslipidemia. IlDong Pharmaceutical Co Ltd. 2014. Avaislable at: https://clinicaltrials.gov/ct2/show/record/NCT022621 43?term=fenofibrate+for+dyslipidemia&rank=3.
24. Guerre-Millo M, Gervois P, Raspé E, et al. Peroxisome proliferator-activated receptor a activators improve insulin sensitivity and reduce adiposity. J BiolChem 2000;275:16638-42.
25. Chong T, Naples M, Federico L, et al. Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia. Atherosclerosis 2006;185:21-31.
26. Cai H, Zhang G, Wang Z, Luo Z, Zhou X. Relationship Between the Use of Statins and Patient Survival in Colorectal Cancer: A Systematic Review and Meta-Analysis. PloS one 2015;10:e0126944.
27. A multicenter study comparing the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia. AstraZeneca. 2007. Avaialable at: https://clinicaltrials.gov/ct2/show/record/NCT004636 06?term=Rosuvastatin&rank=5 [Last accessed 3 January 2014].
28. May HT, Anderson JL, Pearson RR, et al. Comparison of Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Diabetic Patients With Mixed Dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen Study). Am J Cardiol 2008;101:486-9.
29. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM 1995;333:1301-8.
30. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-7.
31. Takagi T, Matsuda M, Abe M, et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008;196:114-21.
32. A study to evaluate fenofibrate combination with statin in chinese patients with dyslipidemic. Abbott. 2011. Avaialble at: https://clinicaltrials.gov/ct2/show/record/NCT01462877?term=fenofibrate+for+dy slipidemia&rank=10 [Last accessed 5 January 2014].
33. Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis 2004;14:215-24.
34. Efficacy and safety of FDC in high risk patients with primary hypercholesterolemia or mixed dyslipidemia (LANCE). AcheLaboratoriosFarmaceuticos S. A. 2011. Available at: http://www.clinicaltrial.gov/ct2/show/NCT01420549?term=NCT01420549&rank =1) [Last accessed 4 January 2014].
35. Lauring B, Taggart AK, Tata JR, Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. SciTransl Med 2012;4:148-15.
36. Goldberg AC. Clinical trial experience with extendedrelease niacin (Niaspan): dose-escalation study. Am J Cardiol 1998;82:35U-8U.
37. Kashyap ML, McGovern ME, Berra K, et al. Longterm safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8.
38. Group H-TC. Effects of extended-release niacin with laropiprant in high-risk patients. NEJM 2014;371:203.
39. Efficacy of nicotine acid on dyslipidemia in patients with metabolic syndrome. GWT-TUD GmbH. 2012. Available at: https://clinicaltrials.gov/ct2/show/NCT00659321?term=NCT00659321&rank=1) [Last accessed 3 January 2014].
40. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. NEJM 2001;345:1583-92.
41. Wierzbicki, A, Hardman, T, Viljoen, A. New lipid-lowering drugs: an update. Int J Clin Prac 2012;66:270-280.
42. Yu XX, Murray SF, Pandey SK, et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 2005;42:362-71.
43. Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-8.
44. Gagné C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469-75.
45. Hussein O, Minasian L, Itzkovich Y, et al. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 2008;65:637-45.
46. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. NEJM 2015.
47. Crespo-Leiro M, Paniagua M, Marzoa R, et al, editors. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation. Transplant Proc 2008;40:3060-3062.
48. Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol Res 2010;40:566-73.
49. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet 2011;377:2181-92.
50. Efficacy and safety of FDC in high risk patients with primary hypercholesterolemia or mixed dyslipidemia (LANCE). AcheLaboratoriosFarmaceuticos S. A. 2011. Available at: http://www.clinicaltrial.gov/ct2/show/NCT01420549?term=NCT01420549&rank =1-[Last accessed 3 January 2014].
51. Tuteja S, Pyrsopoulos NT, Wolowich WR, et al. Simvastatin-Ezetimibe-Induced Hepatic Failure Necessitating Liver Transplantation. Pharmacotherapy 2008;28:1188-93.
52. Nishida HI, Arai H, Nishida T. Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins. J Biol Chem 1993;268:16352-60.
53. Davidson MH. Update on CETP inhibition. J Clin Lipidol 2010;4:394-8.
54. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-2109.
55. Thompson A, Di Angelantonio E, Sarwar N, et al. Association ofcholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008;299:2777-88.
56. Le Goff W, Guerin M, Chapman MJ. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 2004;101:17-38.
57. El Harchaoui K, Van Der Steeg WA, Stroes ES, Kastelein JJ. The role of CETP inhibition in dyslipidemia. Curr Atheroscler Rep 2007;9:125-33.
58. A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease (ILLUMINATE). Pfizer. 2012. Available at: https://clinicaltrials.gov/ct2/show/NCT00134264?term=NCT00134264&rank=1 [Last accessed 3 January 2014].
59. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157:352-60.
60. A study of the safety and efficacy of anacetrapib (MK-0859) when added to ongoing statin therapy in Japanese participants with dyslipidemia (MK-859-051 AM1). Merck Sharp & Dohme Corp. 2013. Avaialbe at: https://clinicaltrials.gov/ct2/show/record/NCT01760460?term=Anacetrapib&rank=5 [Last accessed 3 January 2014].
61. A study of the safety and efficacy of anacetrapib (MK-0859) among participants with hypercholesterolemia when added to ongoing statin therapy (MK-0859-022). Merck Sharp & Dohme Corp. 2013. Avaialble at: https://clinicaltrials.gov/ct2/show/record/NCT01860729?term=Anacetrapib&rank=9 [Last accessed 3 January 2014].
62. Stein EA, Stroes ES, Steiner G, Safety and Tolerability of Dalcetrapib. Am J Cardiol 2009;104:82-91.
63. De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans a randomized phase II dose-response study. Circulation 2002;105:2159-65. •• A study of CETP in relation to atheroseclerosis and dyslipidemia for increasing perfect combination and efficient therapy.
64. Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010;31:480-8.
65. Ballantyne CM, Miller M, Niesor EJ, et al. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J 2012;163:515-21.
66. A Study of dalcetrapib in patients with stable coronary heart disease, with coronary heart disease risk equivalents or at elevated risk for cardiovascular disease. Hoffmann-La Roche. 2012. Avaialble at: https://clinicaltrials.gov/ct2/show/record/NCT015165 41?term=dalcetrapib&rank=3 [Last accessed 3 January 2014].
67. Efficacy and safety study of JTT-705 in combination with pravastatin 40 mg in patients with type II hyperlipidemia. AkrosPharma Inc. 2008. Available at: https://clinicaltrials. gov/ct2/show/record/N CT0068 8896?term=dalcetrapib&rank=2 [Last accessed 3 January 2014].
68. Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006;58:726-41.
69. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends PharmacolSci 2005;26:244-51.
70. A Clinical trial to evaluate the safety and efficacy of ZYH7 compared to fenofibrate in patients with dyslipidemia. Cadila Healthcare Limited. 2013. Avaialble at: https://clinicaltrials.gov/ct2/show/study/NCT01539616?term=fenofibrate+for+dyslipide mia&rank=1 [Last accessed 3 January 2014].
71. Phase III Study of rosuvastatin and fenofibrate versus rosuvastatin in mixed dyslipidemia. IlDong Pharmaceutical Co Ltd. 2014. Available at: https://clinicaltrials.gov/ct2/show/record/NCT022621 43?term=fenofibrate+for+dyslipidemia&rank=3 [Last accessed 3 January 2014].
72. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 2007;56:91-8.
73. Luquet S, Lopez-Soriano J, Holst D, et al. Roles of peroxisome proliferator-activated receptor delta (PPARS) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 2004;86:833-837.
74. Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, doseranging study. The Lancet 2009;374:126-35.
75. Guo Q, Sahoo SP, Wang P-R, et al. A novel peroxisome proliferator-activated receptor α/γ dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology 2004;145:1640-8.
76. Dose ranging study with LT, monotherapy, PPAR. Bristol-Myers Squibb. 2005. Avaialble at: https://clinicaltrials.gov/ct2/show/record/NCT002403 83?term=Muraglitazar&rank=9 [Last accessed 3 January 2014].
77. Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. NEJM 2006;354:1264-72.
78. Awan Z, Seidah NG, MacFadyen JG, et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 2012;58:183-9.
79. Davignon J, Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009;120:163.
80. Tibolla G, Norata GD, Artali R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011;21:835-43.
81. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014;11:563-75.
82. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007;48:763-7.
83. Shan L, Pang L, Zhang R, et al. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. BiochemBiophys Res Commun 2008;375:69-73.
84. Ueshima K, Akihisa-Umeno H, Nagayoshi A, et al. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull 2005;28:247-52.
85. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. NEJM 2007;356:148-56.
86. Aggarwal D, West KL, Zern TL, et al. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 2005;5:30.
87. Cuchel M, Meagher E, Marais A, et al. L5 phase 3 study of microsomal triglyceride transfer protein inhibitor (MTP-i) lomitapide in subjects with homozygous familial hypercholesterolemia (HOFH):56-week results. Atheroscler Suppl 2010;11:14.
88. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380:2007-17.
89. Dias C, Shaywitz A, Cooke B, et al. Effects of AMG 145, a fully human monoclonal antibody against PCSK9, on low-density lipoprotein cholesterol in subjects taking statins: a phase 1, randomized, double-blind, placebo-controlled, ascending multipledose study. J Am CollCardiol 2012;59:E1379-E.
90. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am CollCardiol 2012;59:2344-53.
91. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. The Lancet 2012;380:29-36.
92. Gumbiner B, Udata C, Joh T, et al. The effects of singledose administration of RN316 (PF-04950615), a humanizedIgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin. Circulation 2012;126:A13322.
93. Poirier S, Mayer G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des DevelTher 2013;7:1135-48.
94. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. NEJM 2012;366:1108-18.
95. Ni YGI, Di Marco S, Condra JH, et al. A PCSK9-binding antibody that structurally mimics the EGF (A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res 2011;52:78-86.
96. Zhang L, McCabe T, Condra JH, et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J BiolSci 2012;8:310-27.
97. Liang H, Chaparro-Riggers J, Strop P, et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J PharmacolExpTher 2012;340:228-36.
98. Chaparro-Riggers J, Liang H, De Vay RM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012;287:11090-7.
99. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
100. Vickers KC, Landstreet SR, Levin MG, et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci USA 2014;111:14518-23.
101. ∗ in controlling lipid metabolism gene expression. Mol Cell Biol 2013;33:2339-52.
102. Moore KJ, Rayner KJ, Suárez Y, Fernández-Hernando C. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr 2011;31:49-63.
103. Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of mir-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011;121:2921-31.
104. Rayner KJ, Esau CC, Hussain FN, et al. Inhibitionof mir-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011;478:404-7.
105. Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 2013;19:892-900.
106. Vickers KC, Moore KJ. Small RNA overcomes the challenges of therapeutic targeting of microsomal triglyceride transfer protein. Circ Res 2013;113:1189-91 •• A paper describes the finding regarding identification of small RNA as a novel therapeutic target that coordinately reduces lipid biosynthesis and lipoprotein secretion to suppress circulating apoB lipoproteins.
107. Lee RG, Fu W, Graham MJ, et al. Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein. J Lipid Res 2013;54:602-14.
108. Fu J, Si P, Zheng M, et al. Discovery of new nonsteroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking. Bioorg Med Chem Lett 2012;22:6848-53. •• An original report of the design of new non-steroidal FXR ligands via a ligand-based Phase shape and receptor based induced fit docking (IFD).
109. Huang HI, Yu Y, Gao Z, et al. Discovery and optimization of 1, 3, 4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists. J Med Chem 2012;55:7037-53.
110. Merk D1, Gabler M2, Gomez RC, et al. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR). Bioorg Med Chem 2014;22:2447-60.
111. Merk D, Lamers C, Ahmad K, et al. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist. J Med Chem 2014;57:8035-55.
112. Akwabi-Ameyaw A, Bass JY, Caldwell RD, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg Med Chem Lett 2008;18:4339-43. •• The interesting study introduced a series of GW 4064 analogs, which was followed by desighning other GW 4064 analogs.
113. Akwabi-Ameyaw A, Bass JY, Caldwell RD, et al. FXR agonist activity of conformationally constrained analogs of GW 4064. Bioorg Med ChemLett 2009;19:4733-9.
114. Bass JY, Caravella JA, Chen L, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorg Med Chem Lett 2011;21:1206-13.
115. Akwabi-Ameyaw A, Caravella JA, Chen L, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene. Bioorg Med ChemLett 2011;21:6154-60.
116. Smalley TL Jr, Boggs S, Caravella JA, et al. Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists. Bioorg Med Chem Lett 2015;25:280-4.
117. Richter HG, Benson GM, Blum D. Discovery of novel and orally active FXR agonistsfor the potential treatment of dyslipidemia & diabetes. Bioorg Med Chem Lett 2011;21:191-4. •• The study describes the potential study of FXR agonists and structural activities for different compounds for treatment of dyslipidemia, and diabetes.
118. Rizzo G, Passeri D, De Franco F, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid x receptor and TGR5. Mol Pharmacol 2010;78:617-30
119. 3 output. Hepatology 2011;54:1303-12.
120. D'Amore C, Di Leva FS, Sepe V, et al. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. J Med Chem 2014;57:937-54.
121. Shiohara H, Nakamura T, Kikuchi N, et al. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia. Bioorg Med Chem 2012;20:3622-34.
122. Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3, 5-dichloro-4-(5-isopropyl-6-oxo-1, 6-dihydropyridazin-3-yloxy) phenyl]-3, 5-dioxo-2, 3, 4, 5-tetrahydro[1, 2, 4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor |3 agonist in clinical trials for the treatment of dyslipidemia. J Med Chem 2014;57:3912-23..
123. Howell KL, De Vita RJ, Garcia-Calvo M, et al. Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy. Bioorg Med ChemLett 2010;20:6929-32.
124. Wang Y, Haiqian, Huang W, Zhang H, Zhou J. Synthesis and biological evaluation of ezetimibe analogs as possible cholesterol absorption inhibitors. Lett Drug Des Discov 2011;8:500-5.
125. Arya N, Dwivedi J, Khedkar VM, Coutinho EC, Jain KS. Design, synthesis and biological evaluation of some 2-azetidinone derivatives as potential antihyperlipidemic agents. Arch Pharm (Weinheim) 2013;346:872-81.
126. Arya N, Munde MK, Dwivedi J, Jagdale AY, Jain KS. Design, synthesis, and antihyperlipidemic evaluation of novel 2-[1-(substitutedphenyl)-4-oxoazetidin-2-yl]-5, 6-disubstitutedthieno[2, 3-d]pyrimidin-4 (3H)-ones. Arch Pharm (Weinheim) 2013;346:588-95.
127. Al-Qirim T, Shahwan M, Shattat G, et al. Pharmacological evaluation of novel indole-2-carboxamides as potent lipid-lowering agents in Triton-WR1339-induced hyperlipidemic rats. Z Naturforsch C 2009;64:619-25.
128. Shahwan M, Shattat G, Al-Qirim T, et al. Synthesis and pharmacological evaluation of novel substituted and unsubstituted N-(benzoylphenyl)-1H-indole-2-carboxamides as potent antihypertriglyceridemic agents. Z. Naturforsch C 2010;65:309-16.
129. Shattat G, Al-Qirim R, Al-Hiari Y, et al. Synthesis and anti-hyperlipidemic evaluation of N - (benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats. Molecules 2010;15:5840-9.
130. Shattat G, Tariq Al-Qirim T, Sheikha GA, et al. The Pharmacological effects of novel 5-fluoro-N-(9, 10-dihydro-9, 10-dioxoanthracen-8-yl)-1H-indole-2-carboxamide derivatives on plasma lipid profile of Triton-WR-1339-induced Wistar rats. J Enzyme Inhib Med Chem 2013;28:863-9.
131. Al-Najdawi M, Al-Hiari Y, Al-Qirim T, et al. Synthesis and pharmacological evaluation of novel unsubstitutedindole-anthraquinone carboxamide derivatives as potent antihyperlipidemic agents. Z Naturforsch C 2014;69:21-8.
132. Lee K, Kim M, Lee B, et al. Discovery of indolyl acrylamide derivatives as human diacylglycerol acyltransferase-2 selective inhibitors. Org Biomol Chem 2013;11:849-58.
133. Barylski M, Nikfar S, Mikhailidis DP, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-A meta-analysis of 11 randomized controlled trials involving 21, 295 participants. Pharmacol Res 2013;72:35-44.
134. Nikolic D, Nikfar S, Salari P, et al. Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2013;29:435-51.
135. Andreeva LA, Myasoedov NF, Lyapina LA, et al. Effect of the PRO-GLY-PRO peptide on hemostasis and lipid metabolism in rats with hypercholesterolemia. Dokl Biol Sci 2013;453:333-5.
136. Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007;195:7-16.
137. Kamanna, Vaijinath S, Moti L. Kashyap. Mechanism of action of niacin. Am J Cardiol 2008;101:S20-S26.
138. Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008;62:88-96.
139. Vergeer M, Stroes ES. The pharmacology and offtarget effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol 2009;104:32E-38E.
140. Rangwala SM, Lazar MA. Peroxisome proliferatoractivated receptor y in diabetes and metabolism. Trends Pharmacol Sci 2004;25:331-336.
141. Shen L, Peng H, Xu D, Zhao S. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors. Pharmacol Res 2013;73:27-34.
142. Ladenson PW, McCarren M, Morkin E, et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J Clin Endocrinol Metab 2010;95:1349-1354.